Video content material above is prompted by the next questions:
- Please present an summary of the AGAVE-201 trial, together with its design, affected person inhabitants, and key endpoints.
- What had been the first and secondary endpoints of the AGAVE-201 trial, and the way had been they assessed?
- How did the trial consider the efficacy, security, and tolerability of various dosing regimens of axatilimab in sufferers with recurrent or refractory energetic continual GVHD?
